Cofinimmo SA Overview
| Field | Detail |
|---|---|
| Entity profiled | Aedifica SA/NV (absorbing company of Cofinimmo SA/NV) |
| Legal form | Public limited liability company; public regulated real estate company (RREC / SIR / GVV) under Belgian law |
| Registered office / HQ | Rue Belliard 40 (box 11), 1040 Brussels, Belgium |
| Enterprise number | 0877.248.501 (RLE Brussels) |
| Incorporation | 7 November 2005, Belgium |
| Listings | Euronext Brussels (since 2006 IPO) and Euronext Amsterdam (since November 2019) |
| Ticker | AED (Euronext Brussels/Amsterdam); AOO (German venues) |
| ISIN | BE0003851681 |
| Index membership | BEL 20 (since March 2020, weighting ~4.7% at 30.06.2026), BEL ESG, EPRA Europe (~2.9% weighting), EPRA Belgium (~34.6%), GPR 250, Stoxx Europe 600 |
| Fiscal year end | 31 December |
| Shares outstanding | 92,632,604 (after 1 July 2026 merger issuance) |
| Share price (approx.) | ~EUR 62.30 (Lang & Schwarz weekend quote, 18 Oct 2026; secondary source) |
| Market capitalisation (derived) | ~EUR 5.77 bn (92.63m shares × EUR 62.30). Note: one secondary source quoted EUR 5.2 bn on 16 Oct 2026; the discrepancy likely reflects a stale share count. Company-reported market cap was EUR 5.89 bn at 30.06.2026 on 83.47m shares at EUR 70.60 |
| 52-week range | EUR 60.35 – 80.05 (secondary source, 16 Oct 2026) |
| Employees | Aedifica standalone: ~127–131 (aggregator data, pre-merger). Combined headcount after absorbing Cofinimmo's team: not publicly disclosed |
| Statutory auditor | Aedifica: not confirmed in this research (H1 2026 report contains a limited-review auditor's report; name not captured). Legacy Cofinimmo: KPMG Réviseurs d'Entreprises, represented by Jean-François Kupper (Cofinimmo FY2025 press release, 20.02.2026) |
| Website | www.aedifica.eu (legacy: www.cofinimmo.com) |
| Credit ratings | S&P: BBB+ / stable / A-2 (upgraded March 2026, reconfirmed 20 July 2026). Moody's: A3 / stable, first-time issuer rating (reported 15 Oct 2026 by secondary sources; see Section 21) |
Legacy entity (for reference)
| Field | Detail |
|---|---|
| Legal name | Cofinimmo SA/NV |
| Enterprise number | 0426.184.049 (Brussels Register of Legal Entities) |
| Founded | 1,983 |
| HQ | Avenue de Tervueren / Tervurenlaan 270, Brussels ("The Gradient" building) |
| Former listing | Euronext Brussels, ticker COFB, ISIN BE0003593044; BEL 20 constituent |
| REIT regimes | Belgian RREC, French SIIC, Dutch FBI, Spanish SOCIMI (per company and press descriptions) |
| Shares | 38,096,217 issued at 31.12.2025 |
| Market cap at 31.12.2025 | EUR 3,017 m (share price EUR 79.20) |
| Last CEO / CFO | Jean-Pierre Hanin (CEO) / Jean Kotarakos (CFO) |
| Status | Delisted 1 July 2026; absorbed by Aedifica |
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Aedifica employees (headcount) | — | 131 | 127 |
Note: 2024–2025 headcounts come from data aggregators (roic.ai, Investing.com) and are not company-verified; Cofinimmo headcount was not captured in this research.
Aedifica, following its absorption of Cofinimmo, is Europe's largest listed healthcare real estate investment trust by portfolio value. At 30 June 2026 it owned a EUR 12.5 bn portfolio of 1,723 properties, including a EUR 11.1 bn healthcare book of 924 care properties housing roughly 67,400 residents and 12,900 children across nine countries: Belgium, Germany, Finland, the UK, the Netherlands, France, Ireland, Spain and Italy. Its business model is long-lease, largely triple- or double-net rental to professional care operators, indexed to inflation, with a 15-year WAULT and 99.1% occupancy. The group carries two non-core legacy segments from Cofinimmo: Brussels offices (EUR 874 m) and the Pubstone pub portfolio leased to AB InBev (EUR 468 m). With BBB+ (S&P) and A3 (Moody's) ratings, a 1.9% average cost of debt and EUR 16 m targeted run-rate synergies, the group is positioned as the scale consolidator in a fragmented, demographically driven European care property market.
What the company does
Aedifica is a specialised property investor and developer. It acquires, develops (mostly through pre-let development partnerships), owns and manages real estate used for care. It leases these assets on long-term contracts to private, non-profit and public operators. It does not provide care services itself; operating risk sits with tenants, while Aedifica bears property, re-letting, tenant-credit and valuation risk.
After absorbing Cofinimmo, the group has three reportable activity lines:
-
Healthcare real estate (89% of total portfolio fair value; ~88% of contractual rents at 30.06.2026). Sub-types by fair value of the total portfolio: elderly care homes 60%, mixed-use elderly care 13%, cure centres (acute, rehabilitation and psychiatric clinics) 7%, childcare centres 3%, senior housing 2%, disabled-care facilities 2%, other care 2%.
-
Offices (7% of fair value; EUR 874 m; 23 sites, all in Belgium, largely Brussels CBD), inherited from Cofinimmo.
-
Distribution networks (4% of fair value; EUR 468 m; 776 sites), mainly the Pubstone portfolio of pubs and restaurants in Belgium (577 sites) and the Netherlands (185 sites) leased to AB InBev.
Source: Aedifica 2026 Half Year Financial Report (01.09.2026).
Business and revenue model
| Revenue dimension | Characterisation |
|---|---|
| Revenue type | ~100% rental income (lease/"subscription-like" contractual rent); minor finance-lease interest income, development interest and writeback of sold lease receivables |
| Product vs service vs licensing | No product, service or licensing revenue in the conventional sense; revenue is real-estate rent |
| Contract structure | Long leases. Triple-net (operator bears operating costs, maintenance and vacancy) typical in Belgium, UK, Ireland and Spain, and often the Netherlands and Italy. Double-net (owner keeps roof, structure and facade) typical in Germany, Finland and France |
| Indexation | Annual CPI-linked indexation, usually on the contract anniversary date. H1 2026 like-for-like rental growth of 1.7% was made up of +1.9% indexation, +0.2% reversion and contingent rents, and −0.4% FX |
| Lease duration | WAULT 15 years for total portfolio, 16 years for healthcare (30.06.2026) |
| Occupancy | 99.1% total; 99.7% healthcare (EPRA methodology, 30.06.2026) |
| Gross yield | 6.1% on fair value (healthcare 6.0%, offices 6.3%, distribution 7.4%) |
Value-chain position
Aedifica sits between capital markets (equity, bonds, bank debt, commercial paper) and care operators. It provides long-dated real-estate capital that lets operators run asset-light models. It increasingly acts as a developer-owner: the committed investment programme was EUR 531 m at 30.06.2026, of which EUR 268 m already spent. These are mostly pre-let new builds in Finland, Spain, Ireland, Germany and the UK, with a targeted initial yield on cost of 6–6.5% (actual pipeline average 5.8% after inheriting legacy Cofinimmo Spanish projects).
Customers and end-markets
Customers: About 190 tenant groups (Aedifica H1 2026). Largest exposures by contractual rent: Clariane 12%, Colisée (incl. Armonea) 7%, AB InBev 4%, Emeis 4%, DomusVi 3%, Emera 3%, Azurit Rohr 3%, Vulpia 3%, Maria Mallaband 2%, Finnish municipalities/wellbeing services counties 2%. Others account for 57%.
End-markets: European elderly care (dominant), childcare (Finland), disabled care, acute and rehabilitation care (France, Belgium), mental health, plus Brussels office space and Benelux hospitality (pubs).
Ultimate demand driver: the over-80 population in the EU and UK, which the company puts above 31 million in 2025 and expects to double to over 60 million by 2060.
Company's own description (paraphrased)
In its latest reporting, Aedifica describes itself as a Belgian REIT focused on European healthcare property, especially elderly-care housing. It frames the Cofinimmo merger as creating Europe's leading healthcare REIT, with lower capital costs and sustainable EPS growth as the main value-creation levers (Aedifica H1 2026 report). Cofinimmo's last self-description (FY2025 release) presented it as a 40-year-old owner of care, living and working spaces under the tagline "Caring, Living and Working – Together in Real Estate", with healthcare in nine countries as its core.
Independent characterisation
Analytically, the combined group is a pure-play European healthcare landlord with a non-core diversified tail of about 11% of portfolio value (offices plus pubs). This tail is a legacy of Cofinimmo's history as Belgium's largest diversified REIT. The investment case rests on three things:
-
Inflation-indexed, very long contractual cash flows.
-
A funding-cost advantage from investment-grade ratings and scale.
-
Disciplined capital recycling out of non-core assets.
Its key sensitivities are operator health, especially Clariane and Colisée/Armonea, together about 19% of rent; refinancing costs as legacy cheap hedges roll off; and the trading discount to NAV, which governs whether equity-funded growth is accretive.
Strategy
Stated strategy (themes from latest reporting)
-
Create and lead Europe's healthcare REIT platform: use scale to lower capital costs and grow EPRA EPS sustainably. Management describes the combined platform as built for the next phase of growth in healthcare real estate (H1 2026 report).
-
Healthcare focus with non-core recycling: Aedifica remains focused on healthcare real estate, while continuing asset rotation (EUR 110 m in disposals budgeted for 2026, EUR 54 m achieved by 1 September).
-
Pre-let development as growth engine: pipeline target of EUR 500–750 m, fully pre-let, at a 6–6.5% yield on cost.
-
Balance-sheet discipline: debt-to-assets in the low-40s, no intention to lever above 42–43%, 45% internal ceiling.
-
Sustainability integration: 61% of committed long-term debt linked to sustainability KPIs; net energy use intensity target of 130 kWh/m² by 2030.
-
Dividend growth: payout based on consolidated EPRA Earnings; 2026 DPS guided at EUR 4.20 (+5%).
Strategic initiatives (last 24 months)
| Initiative | Date | Description / targets | Status |
|---|---|---|---|
| Combination with Cofinimmo | May 2025 – Jul 2026 | All-share exchange offer at 1.185 plus merger at 1.1784; ≥EUR 16 m run-rate synergies | Completed; integration ongoing |
| Synergy programme | 2026–2027 | ~EUR 5.5 m in 2026 (one-third of run rate); full ≥EUR 16 m run-rate during 2027 | On track per H1 2026 call |
| BCA divestment remedy | Jan 2026 onward | Divest EUR 300 m of Belgian residential care centres in Flanders and Wallonia over several years to a qualifying buyer | Pending; no 2026 rental impact expected |
| Exit from Sweden | Q1 2025 | Sale of 22 care centres plus education assets (~EUR 93 m) | Completed |
| Financing platform for combined entity | H1 2026 | EUR 620 m sustainability-linked syndicated RCF (8 banks, 5 years, 2×1-year extensions, EUR 100 m accordion); EUR 930 m total long-term bank (re)financing; treasury notes programme raised from EUR 600 m to EUR 1.5 bn | Completed |
| Investment-grade uplift | Mar and Oct 2026 | S&P upgrade to BBB+; Moody's first-time A3 | Completed |
| Potential bond issuance | Autumn 2026 | Management indicated a possible bond issue in autumn, compatible with EUR 5.35 EPS guidance (H1 2026 call) | Unconfirmed |
| Armonea/Colisée agreements | Early 2026 | Property-specific agreements during Colisée's financial recovery plan; Klein Veldekens campus transferred to Vulpia (July 2026) | Ongoing |
| Office repositioning | 2,026 | M10 lease at prime rent; 30-year NATO NCIA usufruct for Bourget 40; Egmont I & II bare-ownership sale | Executed |
Medium-term targets and guidance
| Item | Target / guidance | Source |
|---|---|---|
| FY2026 rental income | EUR 656 m | H1 2026 report |
| FY2026 EPRA Earnings | EUR 436 m | H1 2026 report |
| FY2026 EPRA EPS | EUR 5.35 (+4% y/y); management sees upside potential | H1 2026 report and call |
| FY2026 gross DPS | EUR 4.20 (+5%) | H1 2026 report |
| Average cost of debt 2026 | ~1.9% | H1 2026 report |
| Debt-to-assets year-end 2026 | ~42% | H1 2026 report |
| Run-rate synergies | ≥EUR 16 m during 2027 | H1 2026 report |
| Development yield on cost | 6–6.5% | H1 2026 report |
| Pipeline size target | EUR 500–750 m | H1 2026 call (Alpha Spread summary) |
| Energy intensity | 130 kWh/m² by 2030 | Environmental Data Report (June 2026) |
Products & Services
For a REIT, "products" are asset classes and lease offerings. The catalogue below is organised by segment and country.
Healthcare real estate: by asset type
| Asset type | Description | Target customer | Share of total portfolio FV (30.06.2026) | Lease model |
|---|---|---|---|---|
| Elderly care homes (nursing and care homes) | Residential care centres with 24h nursing care | Private and non-profit care operators (Clariane, Colisée/Armonea, Emeis, DomusVi, Emera, Vulpia, Azurit Rohr, etc.) | 60% | 15–30-year NN/NNN leases, CPI-indexed |
| Mixed-use elderly care | Campuses combining care home, assisted living and service flats | Same operators; German "Seniorenquartier" concepts | 13% | Long leases |
| Cure centres | Specialised acute, rehabilitation and psychiatric clinics (mainly France and Belgium, from Cofinimmo) | Clinic operators, e.g. Clariane, French Red Cross | 7% | Long leases (France WAULT ~7 years) |
| Childcare centres | Day-care centres (Finland) | Private operators (Touhula, Pilke, Norlandia) and municipalities | 3% | 15–20-year NN |
| Senior housing | Independent and assisted living apartments | Operators and housing associations | 2% | Long leases |
| Disabled care facilities | Residential care for physical and mental impairments | Esperi, Finnish foundations, municipalities | 2% | 15–20-year NN |
| Other care properties | Medical office buildings, sport and wellness (e.g. Aspria/David Lloyd), cancer centre (Limerick) | Specialist operators | 2% | Long leases |
Healthcare real estate: by country (30.06.2026)
| Country | Sites | Surface (m²) | Residents | Children | Fair value (EUR Mn) | Contractual rent (EUR Mn) | Gross yield | Key operators |
|---|---|---|---|---|---|---|---|---|
| Belgium | 159 | 1,068,884 | 18,246 | — | 2,784.0 | 166.8 | 6.0% | Korian (Clariane), Armonea (Colisée), Vulpia, Care-Ion, Orelia, Emeis, Vivalto |
| Germany | 156 | 995,712 | 16,177 | — | 2,079.0 | 118.3 | 5.7% | Azurit Rohr, Residenz Management (Specht), Stella Vitalis, Emeis, Vitanas, Compassio, Alloheim |
| Netherlands | 111 | 537,831 | 4,637 | — | 1,197.6 | 76.0 | 6.3% | Korian NL, Martha Flora (DomusVi), Stichting Tantelouise, NNCZ |
| United Kingdom | 119 | 358,833 | 7,803 | — | 1,356.4 (GBP 1,168.7 m) | 87.4 | 6.4% | Maria Mallaband, Bondcare, North Bay Group, Welltower, Emera |
| Finland | 251 | 383,488 | 5,455 | 12,947 | 1,429.7 | 85.4 | 6.0% | Municipalities/wellbeing counties, Attendo, Mehiläinen, Norlandia, Esperi, Touhula, Pilke |
| Ireland | 30 | 147,993 | 2,879 | — | 549.5 | 31.3 | 5.7% | Bartra, Emera, DomusVi |
| Spain | 37 | 240,319 | 5,757 | — | 429.8 | 23.7 | 5.5% | Emera, DomusVi, Reifs, Amavir, Vivalto, Neurocare Home |
| France | 53 | 308,894 | 5,092 | — | 664.3 | 43.5 | 6.6% | Clariane, French Red Cross, DomusVi, Emeis |
| Italy | 8 | 75,873 | 1,337 | — | 215.9 | 12.3 | 5.7% | KOS, Clariane |
| Healthcare total | 924 | 4,117,828 | 67,383 | 12,947 | 10,706.2 | 644.7 | 6.0% | — |
Source: Aedifica H1 2026 report, Section IV.3.1. GBP converted at 0.86161 EUR/GBP.
Offices (legacy Cofinimmo)
| Item | Detail |
|---|---|
| Portfolio | 23 sites, 248,336 m², fair value EUR 874.4 m, contractual rent EUR 55.0 m, gross yield 6.3% (30.06.2026) |
| Location | ~72–75% Brussels CBD (Leopold/European quarter); public-sector tenants ~42% of office rent (Cofinimmo FY2025) |
| Flagship | M10 (Montoyer 10), Brussels CBD, delivered July 2024. BREEAM New Construction Outstanding (Apr 2025), WELL Core Platinum (Sep 2025); new lease signed Q2 2026 at prime rent of ~EUR 400/m²/year; occupancy 57% after that lease |
| Long-lease public asset | Stationsstraat 110, Mechelen: ~15,000 m², renovated, 18-year lease to the Flemish Community's Facilitair Bedrijf (delivered Jan 2025) |
| Long-term usufruct | Bourget 40 (~14,300 m², part of Leopold Square complex opposite NATO HQ): 30-year usufruct agreement signed in 2026 with the NATO Communications and Information Agency |
| Redevelopments | Loi/Wet 85 and Loi/Wet 89 (Brussels CBD) in redevelopment at end-2025 |
| Recent disposal | Egmont I & II bare ownership sold (July 2026; ~EUR 16 m office component of a EUR 27 m post-H1 disposal package) |
| Occupancy | Offices 92.8% (Cofinimmo FY2025) |
Distribution networks (legacy Cofinimmo)
| Item | Detail |
|---|---|
| Pubstone Belgium | 577 pubs/restaurants leased to AB InBev (3% of group rent) |
| Pubstone Netherlands | 185 pubs leased to AB InBev (2% of group rent) |
| Other – Belgium | Tenreuken land reserve (Brussels) and federal police station at Kroonveldlaan 30, Dendermonde |
| Totals (30.06.2026) | 776 sites, 276,700 m², fair value EUR 467.9 m, rent EUR 34.8 m, gross yield 7.4% |
| Rotation | 27 pubs sold in 2025 for EUR 9 m (above fair value); 12 pubs in H1 2026 and 2 more in Q3 2026 |
Public-private partnerships (legacy Cofinimmo)
Six PPP contracts for special-use buildings in Belgium, such as police stations, booked as finance leases (five in Cofinimmo SA/NV, one in FPE Leuze SA/NV). The Edegem police station (HEKLA zone) was sold in 2025 for ~EUR 7 m, a EUR 3 m gain over carrying value. Group finance-lease receivables were EUR 181.6 m non-current and EUR 5.0 m current at 30.06.2026 (after PPA remeasurement).
Development offering (investment programme, 30.06.2026)
| Completion year | Budget (EUR Mn) | Examples |
|---|---|---|
| 2,026 | 217 (projects) + 33 (forward purchases) | Genappe (Korian BE), NRW eco-campus (Compassio), Finnish elderly-care pipeline, Limerick cancer centre (UPMC & Bon Secours), Alicante and Castellón (Vivalto), Gevita Residenz Lörrach (Argentum), Sinnehiem (NL) |
| 2,027 | 207 + 15 | Seniorenquartier Gummersbach (Specht), Crumlin (Bartra), Kilcoole (Muskerry), Córdoba and Oviedo (Amavir), Ourense and Tenerife (DomusVi), Seville (Reifs), Homefield (Emera) |
| 2,028 | 43 | Stadtlohn (Specht), Palma de Mallorca (Emera) |
| 2,030 | 17 | Coham (Clariane, Belgium) |
| Total | 531 (EUR 268 m spent, EUR 263 m to go) | Average initial yield on cost ~5.8% |
Source: Aedifica H1 2026 report, Section IV.3.2.
Pricing model: Rents are set as an initial yield on cost or acquisition value (new developments target 6–6.5%) and indexed annually to local CPI. Individual lease rents are not disclosed.
Financial Narrative
Framework note: REITs do not report "revenue/gross profit/EBITDA" in the industrial sense. The closest equivalents are: revenue = rental income; gross profit ≈ property result after direct property costs; operating income = operating result before result on portfolio; recurring earnings = EPRA Earnings (Cofinimmo: "net result from core activities – group share"). Because the successor entity changed in 2026, tables are presented for both companies.
Legacy Cofinimmo: income statement and KPIs
Sources: Cofinimmo FY2021, FY2022, FY2023, FY2024 and FY2025 annual results releases. FY2025 EPRA Earnings exclude merger-related non-recurring effects (net expense EUR 1.4 m).
EPRA Earnings CAGR FY2021–FY2025 (derived): (245.6/212)^(1/4) − 1 ≈ 3.7%. Per share, EPRA EPS fell from EUR 7.15 to EUR 6.45 (≈ −2.5% CAGR, derived), because equity issuance (EUR 565 m in 2021, 114 m in 2022, 247 m in 2023, 75 m in 2024) and disposals diluted per-share growth. Cofinimmo quantified the FY2025 dilution at −EUR 0.29/share from divestments and −EUR 0.10/share from capital increases.
Legacy Cofinimmo: balance sheet
Source: Cofinimmo FY2025 release (balance sheet 31.12.2025 vs 31.12.2024); FY2022 and FY2023 releases for debt ratios. Structurally negative working capital reflects ~EUR 750 m of short-term sustainable commercial paper, fully backed by undrawn committed long-term lines (headroom EUR 1,031 m after backup at 31.12.2025).
Legacy Cofinimmo: cash flow items
Operating cash flow, free cash flow and dividends paid in cash were not captured in this research. Buybacks: none; treasury share movements relate only to stock-option plan delivery (11,398 treasury shares at 31.12.2025).
Aedifica (successor): income statement and KPIs
Sources: Aedifica financial information page (income statement excerpts FY2023–FY2025); FY2025 annual results press release (13.02.2026). The FY2024 DPS of EUR 3.90 is derived from the disclosed 2.6% increase to EUR 4.00. Rental income CAGR FY2023–FY2025 (derived): 7.2%.
Combined group: H1 2026 snapshot (first period including Cofinimmo)
Source: Aedifica H1 2026 report. The bargain purchase gain (badwill) of EUR 316.1 m arose because the fair value of the Aedifica shares issued was below Cofinimmo's PPA-adjusted net equity; the Q1 2026 release had shown EUR 314.4 m before final adjustment. PPA remeasurements: financial debt +EUR 86.6 m and finance-lease receivables +EUR 30.5 m, amortised over instrument lives (EUR 8.6 m in H1 2026, non-cash).
Commentary on trends, inflections and drivers
1. Earnings plateau versus per-share erosion (Cofinimmo, 2021–2025). Cofinimmo grew absolute recurring earnings modestly (EUR 212 m to EUR 246 m) through heavy healthcare investment financed partly with equity, while selling offices. The model diluted per-share earnings once interest rates rose and the shares traded below NAV. A capital-recycling strategy (about EUR 700 m divested in 2022–2024 and close to EUR 1 bn of office net divestments since 2005) protected the balance sheet but compressed EPS. This culminated in the February 2025 dividend cut from EUR 6.20 to EUR 5.20. The cut, in turn, left Cofinimmo exposed to Aedifica's approach three months later.
2. Valuation cycle. Both companies took fair-value losses in 2023: Cofinimmo's portfolio fell 1.7% in 2023 and 1.9% in 2024 like-for-like, and Aedifica booked −EUR 143.6 m in 2023. The cycle turned in Q1 2025, ending nine consecutive quarters of declines at Cofinimmo. Aedifica recorded six consecutive positive quarters through Q2 2026 (+0.35% like-for-like year-to-date). This drove the IFRS EPS recovery at Aedifica (EUR 0.56 → 4.31 → 5.14).
3. Merger arithmetic. Aedifica guides FY2026 rental income of EUR 656 m (+82% vs FY2025's EUR 361 m) and EPRA EPS of EUR 5.35 (+4%). Accretion comes from Cofinimmo's lower cost of debt (1.5% vs Aedifica's 2.1%), EUR 5.5 m of 2026 synergies (rising to ≥EUR 16 m run-rate during 2027), and the exchange ratio, which priced Cofinimmo at a discount to its NTA. The headline H1 2026 net profit of EUR 509.6 m is dominated by the non-cash badwill and should be excluded from any ROE analysis.
4. Leverage drift. Group debt-to-assets rose from 40.8% to 42.7% on consolidation (Cofinimmo ran ~43%). Management targets the low-40s and around 42% at year-end 2026, below the self-imposed 45% ceiling and far below the 65% RREC legal cap. Net debt/EBITDA of 8.3x is elevated in absolute terms but typical for long-lease European healthcare REITs.
5. Cost of debt is the medium-term headwind. Cofinimmo had disclosed that its average cost of debt would gradually rise toward about 2.3% by 2028 as hedges roll off; its hedge coverage was scheduled to fall from 100% (end-2025) to 71% (end-2029). Aedifica's group hedge ratio of 89.6% has a weighted maturity of only 3.4 years. Rising funding costs are therefore a structural drag that synergies and indexation must offset.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment
| Segment | H1 2025 | H1 2026 |
|---|---|---|
Healthcare real estate rental income (EUR Mn) | 180.8 | 266.3 |
Offices rental income (EUR Mn) | 0 | 15.4 |
Distribution networks rental income (EUR Mn) | 0 | 10.6 |
Total rental income (EUR Mn) | 180.8 | 292.3 |
Revenue by Segment
| Segment | FY2024 | FY2025 |
|---|---|---|
Healthcare gross rental revenues (EUR Mn) | 264.0 | 266.9 |
Offices gross rental revenues (EUR Mn) | 59.9 | 52.9 |
Distribution networks gross rental revenues (EUR Mn) | 34.6 | 34.9 |
Total gross rental revenues (EUR Mn) | 358.5 | 354.7 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Revenue
| Segment | Reported change FY2025 | Like-for-like FY2025 |
|---|---|---|
Healthcare | +1.1% | +2.8% |
Offices | −11.7% | +2.8% |
Distribution networks | +0.8% | +3.2% |
Total | −1.1% | +2.9% |
Segment Overview
| Segment | Fair value (EUR K) | % of portfolio | Net rental income (EUR K) | Property result after direct costs (EUR K) | Segment margin (derived: PRADC / NRI) |
|---|---|---|---|---|---|
Healthcare real estate | 4,680,781 | 76.9% | 258,439 | 247,969 | 95.9% |
Offices | 925,476 | 15.2% | 55,637 | 52,751 | 94.8% |
Distribution networks | 478,798 | 7.9% | 34,115 | 31,835 | 93.3% |
Total | 6,085,055 | 100% | 348,191 | 332,554 | 95.5% |
Segment Overview — Healthcare BE + FR
| Segment | Gross rental yield at 100% occupancy | Net rental yield at 100% occupancy |
|---|---|---|
Healthcare BE + FR | 5.9% | 5.9% |
Healthcare DE + NL | 5.6% | 5.0% |
Healthcare ES + FI + IE + IT + UK | 5.4% | 5.0% |
Offices | 6.4% | 5.8% |
Distribution networks | 6.7% | 6.3% |
Total | 5.9% | 5.6% |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross rental revenues (EUR Mn) | — | — | — | 358.5 | 354.7 |
Rental income net of rental-related expenses (EUR Mn) | — | — | — | 350.9 | 347.6 |
Property result (EUR Mn) | — | — | — | 345.3 | 344.3 |
Property result after direct property costs (EUR Mn) | — | — | — | 331.6 | 332.6 |
Corporate management costs (EUR Mn) | — | — | — | -44.7 | -45.0 |
Operating result before portfolio result (EUR Mn) | — | — | — | 286.8 | 287.6 |
Net interest charges (EUR Mn) | — | — | — | -39.5 | -37.6 |
EPRA Earnings / net result core activities group share (EUR Mn) | 212 | 222 | 241 | 243.8 | 245.6 |
Net result group share (EUR Mn) | — | 483 | -55 | 63.9 | 213.5 |
EPRA EPS (EUR) | 7.15 | — | — | 6.50 | 6.45 |
Net result group share per share (EUR) | — | — | — | 1.70 | 5.61 |
Gross dividend per share (EUR) | 6.00 | 6.20 | 6.20 | 6.20 | 5.20 |
Operating margin (%) | — | — | — | 83.1 | 83.5 |
EPRA Earnings margin on gross rents (%, derived) | — | — | — | 68.0 | 69.2 |
Net margin on gross rents (%, derived) | — | — | — | 17.8 | 60.2 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2021 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Investment properties at fair value (EUR Mn) | — | — | 5,994 | 6,085 |
Total assets (EUR Mn) | — | — | 6,440.0 | 6,437.9 |
Cash and equivalents (EUR Mn) | — | — | 25.8 | 23.8 |
Non-current financial debt (EUR Mn) | — | — | 1,753.3 | 1,588.5 |
Current financial debt (EUR Mn) | — | — | 834.1 | 999.7 |
Total financial debt (EUR Mn) | — | — | 2,587.3 | 2,588.2 |
Net financial debt (EUR Mn, derived) | — | — | 2,561.5 | 2,564.4 |
Total equity incl. minorities (EUR Mn) | — | — | 3,614.4 | 3,590.1 |
Equity attributable to parent (EUR Mn) | — | — | 3,535.0 | 3,511.3 |
Goodwill (EUR Mn) | — | — | 0 | 0 |
Intangible assets (EUR Mn) | — | — | 1.8 | 1.5 |
Working capital (current assets minus current liabilities, EUR Mn, derived) | — | — | -834.9 | -1,041.1 |
Debt-to-assets ratio (%) | 44.2 | 43.8 | 42.6 | 42.8 |
EPRA LTV (%) | — | — | 42.2 | 41.9 |
IFRS NAV per share (EUR) | — | — | 92.84 | 92.20 |
EPRA NTA per share (EUR) | — | — | 93.11 | 92.99 |
Average cost of debt (%) | 1.1 | — | 1.4 | 1.5 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
EPRA capex (investment properties, EUR Mn) | — | — | — | 140 | 131 |
Gross investments (EUR Mn) | — | — | — | — | 111 |
Divestments (EUR Mn) | — | — | — | — | 82 |
Net investments (EUR Mn) | — | — | -1 | — | 29 |
Capital increases (EUR Mn) | 565 | 114 | 247 | 75 | 0 |
Key Financials and Per-Share Data
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Rental income (EUR Mn) | 314.2 | 338.1 | 361.0 |
Net rental income (EUR Mn) | 313.0 | 338.0 | 360.5 |
EPRA Earnings (EUR Mn) | — | 234.6 | 244.8 |
EPRA EPS (EUR) | 5.02 | 4.93 | 5.15 |
Basic and diluted IFRS EPS (EUR) | 0.56 | 4.31 | 5.14 |
Change in fair value of investment properties (EUR Mn) | -143.6 | 15.2 | 75.4 |
Change in fair value of financial instruments (EUR Mn) | -50.9 | -18.7 | -9.6 |
Gross dividend per share (EUR) | — | 3.90 | 4.00 |
EPRA Earnings margin on rental income (%, derived) | — | 69.4 | 67.8 |
Key Financials and Margin Analysis (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Real estate portfolio fair value (EUR Mn) | — | — | 6,285 |
Debt-to-assets ratio (%) | — | 41.3 | 40.8 |
EPRA LTV (%) | — | — | 39.7 |
EPRA NRV per share (EUR) | 84.17 | 86.46 | 87.09 |
EPRA NTA per share (EUR) | 74.18 | 76.63 | 78.40 |
EPRA NDV per share (EUR) | 75.41 | 77.19 | 77.73 |
EPRA vacancy rate (%) | 0.1 | 0.1 | 0.1 |
Net debt / EBITDA (x) | — | — | 7.8 |
Average cost of debt incl. commitment fees (%) | — | — | 2.1 |
Balance Sheet and Margin Analysis (%) (Half-Yearly)
| Metric | H1 2025 | H1 2026 | Change |
|---|---|---|---|
Rental income (EUR Mn) | 180.8 | 292.3 | +62% |
Net rental income (EUR Mn) | 180.6 | 293.3 | +62% |
Operating charges (EUR Mn) | -24.2 | -39.2 | — |
Operating result before portfolio result (EUR Mn) | 156.5 | 254.1 | +62% |
EBIT margin (%) | 86.6 | 86.6 (≈85.5 normalised) | flat |
Financial result excl. FV changes (EUR Mn) | -27.1 | -37.5 | — |
Corporate tax (EUR Mn) | -5.5 | -8.0 | — |
Non-controlling interests in EPRA Earnings (EUR Mn) | -0.3 | -18.9 | — |
EPRA Earnings (EUR Mn) | 123.3 | 189.9 | +54% |
EPRA EPS (EUR) | 2.59 | 2.71 | +5% |
Goodwill impairment, PPA amortisation and badwill (EUR Mn) | 0 | +307.5 | — |
Profit attributable to owners (EUR Mn) | 113.1 | 509.6 | — |
IFRS EPS (EUR) | 2.38 | 7.28 | — |
EPRA cost ratio incl. vacancy (%) | 13.5 | 13.1 | — |
Balance sheet / leverage | 31.12.2025 | 30.06.2026 | — |
Investment properties incl. held for sale (EUR Mn) | 6,285 | 12,478 | — |
Total assets (EUR Mn) | 6,477 | 13,083 | — |
Equity incl. NCI (EUR Mn) | 3,669 | 7,216 | — |
Non-controlling interests (EUR Mn) | 5.6 | 799.5 | — |
Liabilities in debt-to-assets ratio (EUR Mn) | 2,624 | 5,544 | — |
Drawn on credit lines (EUR Mn) | 2,485 | 5,256 | — |
Goodwill (Hoivatilat, EUR Mn) | — | 59.7 | — |
Debt-to-assets (%) | 40.8 | 42.7 | — |
EPRA LTV (%) | 39.7 | 42.2 | — |
Interest cover ratio (x) | 6.2 | 7.6 | — |
Net debt / EBITDA (x) | 7.8 | 8.3 | — |
Hedge ratio (%) | 88.3 | 89.6 | — |
Average cost of debt incl. fees (%) | 2.1 | 1.9 | — |
IFRS NAV per share (EUR) | 77.05 | 76.87 | — |
EPRA NTA per share (EUR) | 78.40 | 77.82 | — |
Financial Analysis
| Ratio | Cofinimmo FY2024 | Cofinimmo FY2025 | Aedifica FY2025 | Aedifica H1 2026 |
|---|---|---|---|---|
ROE (net result group share / avg parent equity) | ~1.8% (derived) | ~6.1% (derived) | not computed | not meaningful (badwill-inflated) |
ROA (net result / avg total assets) | ~1.1% (derived) | ~3.4% (derived) | not computed | not meaningful |
Current ratio (x) | 0.14 (derived) | 0.09 (derived) | not computed | not computed |
Debt/equity (financial debt / total equity) | 0.72 (derived) | 0.72 (derived) | not computed | ~0.73 (derived, drawn debt / equity) |
Net debt / EBITDA (x) | ~8.9 (derived, operating result as EBITDA proxy) | ~8.9 (derived) | 7.8 (reported) | 8.3 (reported) |
Interest coverage (operating result / net interest) | ~7.3x (derived) | ~7.6x (derived) | 6.2x (reported ICR) | 7.6x (reported ICR) |
Asset turnover (gross rents / avg assets) | ~5.6% (derived) | ~5.5% (derived) | not computed | not computed |
Cash conversion cycle | not applicable to REITs | not applicable | not applicable | not applicable |
Revenue by Region
| Country / segment | H1 2025 | H1 2026 |
|---|---|---|
Belgium healthcare (EUR Mn) | 36.3 | 65.3 |
Germany healthcare (EUR Mn) | 32.2 | 49.1 |
Netherlands healthcare (EUR Mn) | 20.6 | 31.5 |
United Kingdom healthcare (EUR Mn) | 45.1 | 43.0 |
Finland healthcare (EUR Mn) | 34.7 | 38.4 |
Ireland healthcare (EUR Mn) | 11.9 | 14.2 |
Spain healthcare (EUR Mn) | 0.1 | 7.5 |
France healthcare (EUR Mn) | 0 | 13.5 |
Italy healthcare (EUR Mn) | 0 | 3.8 |
Belgium offices (EUR Mn) | 0 | 15.4 |
Belgium and Netherlands distribution networks (EUR Mn) | 0 | 10.6 |
Total (EUR Mn) | 180.8 | 292.3 |
Country | Reported change (local currency) | Like-for-like change |
Belgium | +79.9% | +1.6% |
Germany | +52.3% | +2.1% |
Netherlands | +53.0% | +5.1% |
United Kingdom | −4.6% | +5.0% |
Finland | +10.7% | +0.4% |
Ireland | +19.8% | +2.1% |
Spain | +8,615% | +3.4% |
France | new | +0.4% |
Italy | new | −0.8% |
Offices | new | −1.3% |
Distribution networks | new | +2.6% |
Total | +61.6% | +1.7% |
Geographic Revenue
| Country | Aedifica 31.12.2025 (EUR Mn) | Combined 30.06.2026 (EUR Mn) | Share of total, 30.06.2026 |
|---|---|---|---|
Belgium (all segments) | 1,255 | 4,126 (healthcare 2,784 + offices 874 + ~468 distribution, Belgian share partly Dutch) | 33% (incl. offices and distribution) |
Germany | 1,190 | 2,079 | 17% |
Finland | 1,234 | 1,430 | 12% |
United Kingdom | 1,253 | 1,356 | 11% |
Netherlands | 694 | 1,198 (healthcare) | 11% (incl. Pubstone NL) |
France | 0 | 664 | 5% |
Ireland | 433 | 550 | 5% |
Spain | 34 | 430 | 4% |
Italy | 0 | 216 | 2% |
Country Overview
| Country | Fair value (EUR Mn) | % of portfolio | Net rental income (EUR Mn) | Sites | Healthcare WAULT (years) |
|---|---|---|---|---|---|
Belgium healthcare | 1,596.5 | 26.2% | 86.0 | 83 | 16 |
France | 666.9 | 11.0% | 44.1 | 53 | 7 |
Netherlands | 486.9 | 8.0% | 31.2 | 43 | 10 |
Germany | 935.7 | 15.4% | 49.9 | 59 | 18 |
Spain | 444.7 | 7.3% | 47.3 (ES+FI+IE+IT+UK combined) | 31 | 20 |
Finland | 165.9 | 2.7% | (incl. above) | 16 | 16 |
Ireland | 100.4 | 1.7% | (incl. above) | 8 | 12 |
Italy | 216.0 | 3.5% | (incl. above) | 8 | 5 |
United Kingdom | 67.8 | 1.1% | (incl. above) | 3 | 31 |
Offices (Belgium) | 925.5 | 15.2% | 55.6 | 25 | — |
Distribution networks (BE/NL) | 478.8 | 7.9% | 34.1 | — | — |
Capital Markets Data (EUR) and Margin Analysis (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Cofinimmo year-end share price (EUR) | 71.40 | 55.60 | 79.20 |
Cofinimmo 12-month high (EUR) | 90.00 | 71.65 | 79.45 |
Cofinimmo 12-month low (EUR) | 54.15 | 52.15 | 51.80 |
Cofinimmo gross total return (%) | -8.0 | -14.1 | 54.4 |
Cofinimmo market cap year-end (EUR Mn) | 2,625 | 2,118 | 3,017 |
Cofinimmo dividend yield on average price (%) | 8.3 | 10.1 | 7.4 |
Aedifica year-end share price (EUR) | — | — | 67.50 |
Aedifica Price Point Details
| Aedifica price point | Value | Source |
|---|---|---|
31.12.2025 close | EUR 67.50 | H1 2026 report |
H1 2026 range | EUR 66.50 – 80.05 | H1 2026 report |
30.06.2026 close | EUR 70.60 (+~5% YTD at that date) | H1 2026 report |
13–18 Oct 2026 | EUR 61.13 – 62.83 (Lang & Schwarz) | Secondary news source |
YTD to ~18.10.2026 (derived) | ≈ −7.7% price return | Derived |
Since IPO to 30.06.2026 | +108.7% price; total return +361% | H1 2026 report |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
P/EPRA Earnings (2026e) | ~11.6x | EUR 5.35 guidance |
Dividend yield (2026e) | ~6.7% | EUR 4.20 |
P/EPRA NTA | ~0.80x (~20% discount) | EUR 77.82 (30.06.2026) |
P/IFRS NAV | ~0.81x | EUR 76.87 |
EV/Sales (2026e rental) | ~16.8x | Market cap ~EUR 5.77 bn plus drawn debt EUR 5.26 bn, divided by EUR 656 m; excludes cash and minorities |
EV/EBITDA | Not computed (FY EBITDA not guided) | — |
Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Cofinimmo gross DPS (EUR) | 6.00 | 6.20 | 6.20 | 6.20 | 5.20 |
Aedifica gross DPS (EUR) | — | — | — | 3.90 | 4.00 |
Credit Ratings
| Agency | Rating | Outlook | Date / notes |
|---|---|---|---|
S&P Global | BBB+ long-term; A-2 short-term | Stable | Upgraded from BBB on 13.03.2026; reconfirmed 20.07.2026 |
Moody's | A3 issuer (first-time), also covering ~EUR 1.5 bn senior unsecured notes | Stable | Reported 15.10.2026 by secondary sources. One source notes Aedifica's IR page shows the A3 dated 10.09.2026; the discrepancy is unresolved |
Fitch | Not rated (not identified) | — | — |
Legacy Cofinimmo (S&P) | BBB / A-2, positive watch | — | Rated by S&P since 2001; confirmed 25.03.2025 |
Maturity Year Details
| Maturity year | Committed lines (EUR Mn) | Utilisation (EUR Mn) | Short-term treasury notes (EUR Mn) |
|---|---|---|---|
| 2026 | 122 | 112 | 1,003 |
| 2027 | 990 | 832 | 80 |
| 2028 | 1,643 | 1,184 | 0 |
| 2029 | 563 | 332 | 0 |
| 2030 | 1,452 | 932 | 0 |
| 2031 | 1,668 | 671 | 0 |
| 2032 | 95 | 50 | 0 |
After 2032 | 299 | 149 | 0 |
Total | 6,832 | 4,262 | 1,083 |
Bond Details
| Bond | Nominal | Coupon | Maturity | ISIN |
|---|---|---|---|---|
Straight bond 2016–2026 | EUR 70 m | 1.70% | 26.10.2026 | BE0002267368 |
Sustainable bond 2022–2028 | EUR 500 m | 1.00% | 24.01.2028 | BE0002838192 |
Sustainable bond 2020–2030 | EUR 500 m | 0.875% | 12.02.2030 | BE6325493268 |
Margin Analysis (%)
| Hedge component | 2026H1 | 2026YE | 2027YE | 2028YE | 2029YE |
|---|---|---|---|---|---|
Fixed-rate debt (% of projected debt) | 39 | 37 | 35 | 22 | 21 |
Swaps (% of projected debt) | 51 | 51 | 45 | 40 | 28 |
Unhedged floating (% of projected debt) | 10 | 12 | 20 | 38 | 51 |
Analyst Conclusions
Management guidance (FY2026)
Rental income of EUR 656 m; EPRA Earnings of EUR 436 m; EPRA EPS of EUR 5.35 (+4%), with management flagging possible upside; gross DPS of EUR 4.20 (+5%); average cost of debt ~1.9%; debt-to-assets ~42% at year-end; disposals of EUR 110 m (EUR 54 m done); synergies of EUR 5.5 m in 2026, rising to ≥EUR 16 m run-rate during 2027. The Belgian EUR 300 m remedy sale is not expected to affect 2026 rental income. The guidance assumes 0.8695 EUR/GBP for H2 2026.
Consensus expectations
FY2026 EPRA EPS consensus is ~EUR 5.33 (cited at the H1 call). Analytically, FY2027 should benefit from full-year consolidation, at least EUR 10 m of incremental synergies (≈ +EUR 0.11/share, derived) and pipeline deliveries (~EUR 222 m due in 2027). These are offset by rising hedge roll-off costs and a full year of the larger share count.
Bull case
-
Accretive platform with upside to synergies: H1 2026 EPS +5% before most synergies, a 0.80x P/NTA entry point and ~6.7% yield. Delivering ≥EUR 16 m synergies plus indexation could sustain mid-single-digit EPS growth.
-
Credit re-rating lowers the cost of capital: BBB+ and A3 ratings support cheap unsecured bonds to term out EUR 1.1 bn of treasury notes, protecting the ~1.9% debt cost as Cofinimmo-legacy hedges expire.
-
Operator recovery drives values: rising operator occupancy (+232 bps in Germany, +247 bps in the Netherlands) and rent covers (UK 2.3x) underpin six straight quarters of valuation gains, which could close the NAV discount.
Bear case
-
Refinancing cliff: unhedged floating debt rises from 10% to 51% of projected debt by 2029. With 8.3x net debt/EBITDA, each 100 bps rise in rates on newly unhedged debt would be a material EPS headwind.
-
Tenant concentration and operator fragility: Clariane (12%) and Colisée/Armonea (7%) remain exposed to wage inflation and staffing shortages. Any renewed operator distress would hit both rents and valuations.
-
Contingent liabilities and forced sales: up to ~EUR 108 m of German and Dutch transfer taxes, a EUR 300 m Belgian sale with constrained buyer pool, and non-core offices (M10 57% let) could dilute NAV and earnings.
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst |
|---|---|
| 26.10.2026 | Repayment/refinancing of the EUR 70 m 1.70% legacy Cofinimmo bond |
| Autumn 2026 | Possible inaugural combined-entity unsecured bond (post-Moody's A3) |
| 18.11.2026 | Q3 2026 results: synergy tracking, guidance confirmation or raise |
| H2 2026 – 2027 | Dutch Tax Authority ruling on merger exemption (~EUR 63.4 m); German RETT position (~EUR 45 m) |
| 2026–2027 | Announcement of the buyer and pricing for the EUR 300 m Belgian remedy portfolio |
| 17.02.2027 | FY2026 results and FY2027 guidance (first full-year combined outlook) |
| 2,027 | Full ≥EUR 16 m synergy run-rate; delivery of EUR 222 m of pipeline projects |
| Ongoing | Office disposals and leasing (M10, Loi 85/89 redevelopments); Pubstone rotation |
| Ongoing | Colisée/Armonea performance post-restructuring; Clariane credit |
| 11.05.2027 | AGM; payment of the EUR 4.20 FY2026 dividend |
Analyst verdict
Cofinimmo as a listed equity is gone. Its legacy lives on inside a materially stronger Aedifica, and the investment question now is whether the combined group can convert scale into durable per-share growth. The first evidence is encouraging. H1 2026 EPRA EPS rose 5% to EUR 2.71 before most synergies, and FY2026 guidance of EUR 5.35 sits marginally above consensus. Both rating agencies now place the group comfortably in investment grade (BBB+ / A3). The operating base is defensive: a 15-year WAULT, 99.1% occupancy, CPI-indexed rents across nine countries, and a demographic tailwind that every market review in the company's own reporting describes as structural.
Against this, the balance sheet is fuller than at end-2025. Net debt/EBITDA is 8.3x and debt-to-assets 42.7%, and the hedge book thins sharply after 2027. Earnings growth beyond 2027 therefore depends on three things: synergies, development deliveries at 6%-plus yields, and refinancing discipline, chiefly terming out more than EUR 1 bn of treasury notes into bonds at a sensible spread. The inheritance from Cofinimmo also brings unwanted baggage: about 11% of value in offices and pubs, legacy Spanish and German development disputes, two transfer-tax contingencies totalling up to ~EUR 108 m, and a regulator-mandated EUR 300 m Belgian sale.
At ~EUR 62, the shares trade around 0.80x EPRA NTA, ~11.6x 2026e EPRA earnings and a ~6.7% prospective yield. That pricing already discounts much of the refinancing and concentration risk. The decisive monitorables are the Q3 and FY2026 prints, the Dutch tax ruling, and evidence that non-core disposals and remedy sales can be executed near book value. Failure on these points would turn the NAV discount from an opportunity into a verdict.
Principal sources consulted
-
Aedifica SA/NV: 2026 Half Year Financial Report (01.09.2026); Q1 2026 interim report and slides (19.05.2026); FY2025 annual results press release (13.02.2026); legal merger completion release (01.07.2026); new Board / share issuance release (10.03.2026); merger proposal release (30.04.2026); Board merger report (04.05.2026); executive CVs (Daerden, van Aelst, Bicici, Dumont); financial information web page.
-
Cofinimmo SA/NV: FY2025 annual results (20.02.2026); FY2024, FY2023, FY2022 and FY2021 annual results; H1 2022, Q3 2022, Q1–Q3 2024 releases; Q1 2026 release (22.04.2026); EGM merger approval release (30.06.2026); change-of-control release (10.03.2026); roadshow presentations 2022–2024; investor reports page.
-
Belgian Competition Authority: press release No. 2/2026 (21.01.2026).
-
Secondary and market sources (flagged in text): Stibbe, manda.be, La Libre Belgique, Bolero/KBC Securities, Alimarket, MLex, LaingBuisson, CB Insights, Parqet, Quartr, Alpha Spread, Investing.com, RTTNews, Zonebourse/Fortuneo, MarketScreener, AD HOC NEWS, roic.ai, Real Asset Insight, CRE Herald, earnings call transcripts (Cofinimmo FY2024 and FY2025; Aedifica FY2025 and H1 2026).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure in role | Prior roles / background | Education | Birth year |
|---|---|---|---|---|---|
Stefaan Gielens | CEO and Executive Director (only executive on the board) | Since Aedifica's early years (2006 per aggregator) | Founding CEO of Aedifica | Not captured | ~1965 (aggregator age 61) |
Ingrid Daerden | Chief Financial Officer | Since September 2018 | ~10 years real-estate finance at ING Belgium; Cofinimmo 2008–2016 (Investor Relations Manager, then Head of Treasury & Project Finance); CFO of OTN Systems | Master in Business Engineering, KU Leuven | 1974 |
Charles-Antoine van Aelst | Chief Investment Officer | CIO since October 2017; ExCo since June 2020 | Joined Aedifica in 2008 as Corporate Analyst/IR; Investment Manager (2011); Investment Officer (2016) | Master of Applied Economics (Antwerp); Master of Financial Management (Vlerick); Postgraduate Certificate in Real Estate (KU Leuven) | 1986 |
Yeliz Bicici | Chief Operating Officer | Since July 2026 | Cofinimmo 2008–2026: Property Manager, Area Manager, Development Manager, Head of Development (2014), COO (July 2018); earlier Robelco (2001–2008) and Uniway | Dual Master in Real Estate (KU Leuven 2009; Antwerp Management School 2012); Harvard Business School GMP (2021); postgraduate energy engineering and financial analysis (Ghent) | 1976 |
Roel Dumont | Chief Human Resources Officer | Since July 2026 | Alken-Maes Breweries HR (2000–2008); Tessenderlo Group global HR roles incl. VP HR (13 years); labour court judge since 2007; Cofinimmo ExCo member for HR and internal communication from 2021 | Master in Law (KU Leuven); business administration (EMS) | 1973 |
Sven Bogaerts | Chief M&A Officer / General Counsel (per aggregator; current ExCo title not confirmed) | General Counsel role from June 2020 (aggregator) | Previously Eubelius (law firm) per aggregator | Not captured | ~1978 (aggregator) |
Board of Directors
| Name | Role | Origin | Committees (where disclosed) |
|---|---|---|---|
Jean Hilgers | Chair (from 01.07.2026; Vice-Chair 10.03–30.06.2026) | Cofinimmo (former Chair) | Chair of the Nomination and Remuneration Committee (from March 2026) |
Serge Wibaut | Independent Director (Chair until 30.06.2026) | Aedifica | Not captured |
Stefaan Gielens | Executive Director, CEO | Aedifica | — |
Ann Caluwaerts | Independent Director | Cofinimmo | Nomination and Remuneration Committee |
Nathalie Charles | Independent Director | Cofinimmo | Audit and Risk Committee |
Xavier de Walque | Independent Director | Cofinimmo | Audit and Risk Committee |
Fifth Cofinimmo-origin director | Independent Director | Cofinimmo | Name not captured in this research |
Marleen Willekens | Independent Director (since 2017, aggregator) | Aedifica | Not captured |
Elisabeth May-Roberti | Independent Director (since 2015, aggregator) | Aedifica | Not captured |
Ms van Velthuizen-Lormans | Independent Director (aggregator listing) | Aedifica | Not captured |
Remaining Aedifica-origin director | Independent Director | Aedifica | Not captured |
Major Shareholders
| Shareholder | Stake | Date / source |
|---|---|---|
BlackRock, Inc. | 5.79% (4,829,214 voting rights) | Notified 12.03.2026; on 83.47m shares |
Stichting Pensioenfonds ABP | 5.13% (4,281,807) → 4.76% (4,411,528 on enlarged base) | Notified 02.06.2026 and 01.07.2026 |
Others below 5% | ~89–90% | Aedifica H1 2026 report |
Free float (Euronext definition) | 100% | — |
Treasury shares | 855 | 30.06.2026 |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Positioning vs Aedifica |
|---|---|---|
Welltower (US) | UK and pan-European care homes; also an Aedifica tenant (15 UK sites) | Global giant with operating platforms; competes for large UK deals; much larger cost of capital advantage in USD markets |
Care Property Invest (BE) | Belgian and Dutch/Spanish care homes | Smaller Belgian REIT; now Belgium's #2 pure-play healthcare REIT after the merger |
Primary Health Properties (UK; merged with Assura in 2025) | UK and Irish primary-care/medical property | Adjacent segment (GP surgeries) rather than care homes |
Target Healthcare REIT (UK) | UK care homes | Smaller UK specialist |
Impact Healthcare REIT (UK) | UK care homes | Smaller UK specialist |
Praemia Healthcare (formerly Icade Santé, FR) | French clinics and nursing homes, expanding in Europe | Main French/Italian rival for Cofinimmo-legacy assets |
Hemsö (SE) / Nordic players | Nordic social infrastructure | Competes in Finland |
Healthcare Activos (ES/PT) | Spanish care homes | Spanish competitor |
Nrep / unlisted funds (e.g. Nordic care JV) | Finnish care homes (a EUR 400 m Finnish JV reported in 2025) | Private capital competitor |
Omega Healthcare / Sabra (US) | UK care homes | US REITs active in UK |
Brussels office landlords (e.g. AG Real Estate / Befimmo, Allianz, Axa IM) | Brussels CBD offices | Competition for public and EU-institution tenants |
Competitor Detail
| Metric | Aedifica (combined) |
|---|---|
Rental income | EUR 656 m (FY2026 guidance) |
Portfolio value | EUR 12.5 bn |
Recurring EPS growth | +4% (2026e) |
EBIT margin | 86.6% (H1 2026) |
R&D intensity | n/a (real estate) |
Credit rating | BBB+ (S&P) / A3 (Moody's) |



